Redcare Pharmacy stock gets higher MPCM target at 125 euros

MPCM has raised its price target for Redcare Pharmacy from 120 to 125 euros and retained its buy rating, according to Boerse Express in a report published Monday, November 9. The analyst action was made on November 3 and increases the target by 4.17 percent without changing the underlying recommendation.

Redcare Pharmacy stock traded at 73.68 euros on Lang & Schwarz at 11:05 CET on Monday, November 9, 4.44 percent above the Xetra close of Friday, November 6. The shares therefore remain below both the revised MPCM target and the 97-euro target that Jefferies has left unchanged while also maintaining a buy rating.

Growth remains the central test

The analyst reassessment follows Redcare Pharmacy's third-quarter figures. The company reported revenue of 846.7 million euros, up 18 percent from the prior-year quarter, while adjusted EBITDA margin rose to 3.4 percent from 2.4 percent. Management also confirmed its 2026 revenue growth outlook of 16 to 18 percent.

Prescription revenue was the main growth driver, while the company also reported more than 15 million active customers in Europe and a repeat-order rate above 90 percent in the third quarter. For investors, the key question is whether prescription growth and rising operating leverage can offset the lower-margin characteristics of the broader online pharmacy business.

The higher MPCM target provides a more constructive valuation signal, but it is not a guarantee of future returns. Execution against the 2026 outlook, customer growth and margin development remain the main factors for the investment case. The unchanged Jefferies target also shows that analyst views are not moving uniformly.

German equities remain the wider market backdrop for Redcare Pharmacy stock; see current AEX market developments.

View the real-time quote of Redcare Pharmacy stock for the latest market indication.

Further analyst updates and operating milestones will remain important as Redcare Pharmacy approaches its full-year results. More news and analyses on Redcare Pharmacy stock.